연구성과로 돌아가기

2024 연구성과별 연구자 정보 (1481 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse Moon, Joon Ho Moon, JH 11 Kyungpook Natl Univ Hosp, Daegu, South Korea
Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse Sohn, Sang Kyun Sohn, SK 12 Kyungpook Natl Univ Hosp, Daegu, South Korea
Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse Mattsson, Jonas Mattsson, J 13 Princess Margaret Hosp, Hans Messner Allogene Transplant Program, Div Med Oncol & Hematol, Toronto, ON, Canada
Multicenter Retrospective Analysis on the Clinical Benefit of Post-Transplant Tyrosine Kinase Inhibitor (TKI) Maintenance Therapy in Ph-Positive Acute Lymphoblastic Leukemia Suggests Improved GvHD-Free, Relapse Free Survival and Non-Relapse Mortality, but Not the Risk of Relapse Kim, Dennis Dong Hwan Kim, DDH 14 Princess Margaret Hosp, Hans Messner Allogene Transplant Program, Div Med Oncol & Hematol, Toronto, ON, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Garcia-Horton, Alejandro Garcia-Horton, A 1 McMaster Univ, Juravinski Hosp, Dept Oncol, Ancaster, ON, Canada AAE-4477-2021 Garcia-Horton, Alejandro
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Garcia-Horton, Alejandro Garcia-Horton, A 1 McMaster Univ, Canc Ctr, Dept Oncol, Ancaster, ON, Canada AAE-4477-2021 Garcia-Horton, Alejandro
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Ahmad, Imran Ahmad, I 2 Hop Maison Neuve Rosemont, Montreal, PQ, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Lepic, Kylie Lepic, K 3 McMaster Univ, Juravinski Hosp, Dept Oncol, Hamilton, ON, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Lepic, Kylie Lepic, K 3 McMaster Univ, Canc Ctr, Dept Oncol, Hamilton, ON, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Lemieux, Christopher Lemieux, C 4 CHU Quebec Univ Laval, Ctr Integre Cancerol, Quebec City, PQ, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Sanford, David Sanford, D 5 Univ British Columbia, British Columbia & Vancouver Gen Hosp, Dept Med, Leukemia Bone Marrow Transplant Program,Div Hemato, Vancouver, BC, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Elemary, Mohamed Elemary, M 6 Univ Saskatchewan, Prov Hematol & Blood & Marrow Transplant Program, Saskatchewan Canc Agcy, Saskatoon, SK, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Jamani, Kareem Jamani, K 7 Univ Calgary, Tom Baker Canc Ctr, Cumming Sch Med, Calgary, AB, Canada
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Al Zahrani, Mohsen Al Zahrani, M 8 Minist Natl Guard Hlth Affairs, King Abdulaziz Med City, Riyadh, Saudi Arabia
Multicenter Survey on the Practice Patterns of Post-Transplant Maintenance Treatment in FLT3-ITD Acute Myeloid Leukemia and Philadelphia Positive Acute Lymphoblastic Leukemia: What Is the Common Institutional Policy for Duration of Therapy? Alhumaid, Muhned Alhumaid, M 9 King Fahad Med City, Dept Hematol, Riyadh, Saudi Arabia AHA-2993-2022 Alhumaid, Muhned
페이지 이동: